Skip to content
Back to announcement

20250620_PYFA_Ringkasan Risalah//Risalah RUPS_31897333_lamp1.pdf

RUPS minutes Needs review PYFA

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 5

Page 1
                           ANNOUNCEMENT OF SUMMARY OF MINUTES
                          ANNUAL GENERAL MEETING OF SHAREHOLDERS
                                   PT PYRIDAM FARMA TBK.

The Board of Directors of PT Pyridam Farma Tbk. (hereinafter referred to as the “Company”) hereby
informs to the Shareholders of the Company that it has held the Annual General Meeting of
Shareholders (hereinafter referred to as the “Meeting” or “AGMS”) based on the Financial Services
Authority (”OJK”) Regulation No. 16/POJK.04/2020 dated April 20th, 2020 regarding the
Implementation of the Electronic General Meeting of Shareholders of a Public Companies and OJK
Regulation No. 15/POJK.04/2020 dated April 20th, 2020 regarding The Planning and Procedures for
General Meeting of Shareholders of Public Companies, which are as follows:
    A. Day/Date         : Wednesday, 18th June 2025
        Time            : 14.38 p.m. Jakarta time
        Venue           : Sinar Mas Land Plaza Sudirman, 12th floor, Jl. Jend. Sudirman No. Kav. 21,
                          Kuningan, South Jakarta, Indonesia
        Meeting Agenda:
         1. Approval of the Annual Report, Sustainability Report and Ratification of the Company’s
            Financial Statements for the financial year which ended on December 31st, 2024 as well
            as granting of full release and discharge of responsibilities (volledig acquit et de charge)
            to the members of the Board of Directors and members of the Board of Commissioners
            for the management and supervisory actions carried out for the financial year ended on
            December 31st, 2024.
         2. Determination of the allocation of the Company’s net profit/loss for the financial year
            which ended on December 31st, 2024.
         3. Determination of Remuneration of Members of the Board of Directors and Board of
            Commissioners of the Company for the Financial Year in 2025.
         4. Appointment of Public Accountant Firm to perform audit on the Company’s Consolidated
            Financial Statements for the financial year which ended on December 31st, 2025.
         5. Reports on the Realization of the Use of Proceeds from the Continuing Public Offering of
            Pyridam Farma Sustainable Bonds I Phase II Year 2023, Public Offering of Pyridam Farma
            Sustainable Bonds I Phase III Year 2024, Rights Issue I (Limited Public Offering with Pre-
            emptive Rights) and Issuance of Series I Warrants.
         6. Approval of changes to the composition of the Company’s management.

    B. Members of the Board of Directors and the Board of Commissioners of the Company who
       were physically present at the Meeting :

                BOARD OF DIRECTORS :
                President Director               : LEE YAN GWAN
                Director                         : dr. WIDJANARKO BROTOSAPUTRO
                Director                         : YENFRINO GUNADI
Page 2
            Director                       : BEDJO STEFANUS

            BOARD OF COMMISSIONERS :
            Independent Commissioner : MAURA LINDA SITANGGANG

C. Members the Board of Commissioners of the Company who were present virtually at the
   Meeting:

            BOARD OF COMMISSIONERS :
            President Commissioner   : ROBBY YULIANTO
            Independent Commissioner : CHARLES D. MARPAUNG

D. The Meeting was attended by 7.018.391.981 shares with valid voting rights or equivalent to
   62,46% from the total shares with valid voting rights issued by the Company.

E. In the Meeting, each shareholder/proxy was given the opportunity to seek inquiry and/or
   provide opinions, related to each Meeting agenda.

F. The decision-making mechanism in the Meeting is as follows:
   Meeting decisions were made by way of deliberation to reach consensus, if there were
   shareholders or their proxies who vote against or abstain, the voting would be held.

G. The number of shareholders/proxies who sought inquiry and/or provided opinions as well as
   the results of the vote on each agenda of the Meeting are as follows:

         AGMS        The number of                           Voting Results
                  Shareholders/Proxies       Affirmative      Disapproval        Abstain
                   who sought inquiry
                 and/or provide opinions
     1                                     7.017.426.481
                                                            965.500 shares    214.100 shares
                                               shares
                           1                                  (0,0099% of      (0,00101% of
                                           (99,98909% of
                                                            those present)    those present)
                                           those present)
     2                                     7.018.168.181
                                                                              223.800 shares
                                               shares       0 shares (0% of
                           0                                                   (0,00102% of
                                           (99,99898% of    those present)
                                                                              those present)
                                           those present)
     3                                     7.017.202.681
                                                            965.500 shares    223.800 shares
                                               shares
                           0                                  (0,0099% of      (0,00102% of
                                           (99,98908% of
                                                            those present)    those present)
                                           those present)
Page 3
     4                                      7.018.177.881
                                                                                  214.100 shares
                                                shares         0 shares (0% of
                            0                                                      (0,00101% of
                                            (99,99899% of      those present)
                                                                                  those present)
                                            those present)
     5                                      7.018.164.981
                                                                                   3.200 shares
                                                shares         223.800 shares
                                                                                   (0,0000455%
                            0               (99,9988345%        (0,00102% of
                                                                                      of those
                                               of those        those present)
                                                                                      present)
                                               present)
     6                                      7.018.168.181
                                                                                  223.800 shares
                                                shares         0 shares (0% of
                            0                                                      (0,00102% of
                                            (99,99898% of      those present)
                                                                                  those present)
                                            those present)


H. Whereas in the Company’s Meeting the following decisions with unanimous votes have been
   made:


     I.   First Agenda
          1. Approved the Annual Report and Sustainability Report and ratified the Company’s
               Finansial Statements for the financial year which ends on December 31st 2024;
          2. Upon the approval of the Company’s Annual Report, including the Sustainability
               Report and the Board of Commissioners’ Duties for the financial year which ends on
               December 31st, 2024, and the ratification of the Company’s Consolidated Financial
               Statement which ends on December 31st, 2024, which has been audited by the
               Public Accounting Firm Purwanto, Sungkoro & Surja, a member firm of Ernst &
               Young, in all material respects, the Meeting hereby grants full release and discharge
               (volledig acquit et de charge) to all members of the Board of Directors and the Board
               of Commissioners for the management and supervisory actions that have carried
               out during the financial year ended December 31st, 2024, to the extent such action
               is not a criminal act and reflected in the Company’s Consolidated Financial
               Statement, Sustainability Report and Annual Report for Financial Year which ends
               on December 31st, 2024.

    II.   Second Agenda
          Approved the use of the Company’s Net loss for the financial year which ends on
          December 31st, 2024 in the IDR 330,246,365,580, and shall not set aside profits as
          reserves and distribute dividends for the financial year 2024.

   III.   Third Agenda
Page 4
      Grants authority and power to the Board of Commissioners of the Company to
      determine the amount of salary or honorarium and other allowances for the members
      of the Board of Commissioners and Board of Directors of the Company for the financial
      year which ends on December 31st, 2025, based on the Decision of the Meeting of the
      Board of Commissioners of the Company with total salary, honorarium, bonuses, and
      other allowances for the Board of Directors and the Board of Commissioners while
      taking into consideration the financial conditions and performance of the Company.

IV.   Fourth Agenda
      Authorized the Board of Commissioners to appoint a Public Accounting Firm to perform
      the audit of the Company's Financial Report which will end on December 31st, 2025 by
      considering the proposal of the Company's Board of Commissioners and taking into
      account the recommendations of the Company's Audit Committee and authorizing the
      Company's Directors to determine the amount of the public accountant's honorarium
      and other requirements, considering the Company’s needs to monitor and assess
      performance and to consider prospective public accountants to be appointed based on
      input from the Company's Board of Commissioners and the Company's Audit
      Committee and to consider other objectives deemed necessary in making decisions.

V.    Fifth Agenda
      Approved the report on the implementation of the use of proceeds from the Public
      Offering of Pyridam Farma Sustainable Bonds I Phase II Year 2023 in the amount of IDR
      395,686,126,200 as stated in the Use of Proceeds from the Public Offering of of
      Pyridam Farma Sustainable Bonds I Phase II Year 2023, Letter No.: 005/PYFA-CS/I/2025
      dated January 14, 2025, report on the utilization of proceeds from the Public Offering
      of Pyridam Farma Sustainable Bonds I Phase III Year 2024 in the amount of IDR
      105,299,258,721, as stated in the Report on the Realization of Use of Proceeds from the
      Public Offering of of Pyridam Farma Sustainable Bonds I Phase III Year 2024, Letter No.:
      007/PYFA-CS/I/2025 dated January 14, 2025, report on the utilization of all proceeds
      from the Rights Issue with Pre-Emptive Rights I ("PMHETD I") amounting to IDR
      1,065,099,254,694 and proceeds from the conversion of Series I Warrants into shares
      amounting to IDR 1,504,800, as referred to in the Report on the Realization of Proceeds
      from the Limited Public Offering to Shareholders for the Issuance of Series I Warrants
      No. 006/PYFA-CS/1/2025, dated January 14, 2025, and the report on the Realization of
      Proceeds from the Rights Issue with Pre-Emptive Rights I and the Issuance of Series I
      Warrants No. 084/PYFA-CS/VII/2024, dated July 15, 2024.


VI.   Sixth Agenda
      1. Approved the honorable discharge of all current members of the Board of Directors
          and Board of Commissioners of the Company, and subsequently appointed the new
Page 5
    members of the Board of Directors and Board of Commissioners with the following
    composition:

    Board of Directors:

    1.   LEE YAN GWAN as President Director;
    2.   YENFRINO GUNADI as Director;
    3.   BEDJO STEFANUS as Director;
    4.   ANTES EKO PRASETIO as Director; and
    5.   SINTA LESTARI NINGSIH as Director.


    Board of Commissioners:

    1.   ROBBY YULIANTO as President Commissioner;
    2.   dr. WIDJANARKO BROTOSAPUTRO as Commissioner;
    3.   CHARLES D. MARPAUNG as Independent Commissioner; and
    4.   MAURA LINDA SITANGGANG as Independent Commissioner.

    The dismissal and appointment shall be effective as of the close of this Meeting and
    shall remain valid until the end of the respective term of office at the Annual
    General Meeting of Shareholders to be held in 2030, without prejudice to the right
    of the General Meeting of Shareholders to dismiss them at any time;

2. Granted authority, with the right of substitution, to the Board of Directors of the
   Company, either jointly or individually, to take all necessary actions in connection
   with the above resolutions, including but not limited to preparing, signing, and
   delivering all required documents, stating such resolutions in a separate notarial
   deed, and further notifying the relevant authorities of the changes in the Company’s
   management composition in accordance with the applicable laws and regulations.

                      Jakarta, June 20th, 2025
           The Board of Directors of PT Pyridam Farma Tbk.

File

File Open PDF
Source IDX
Size0.59 MB
Published20 Jun 2025
Pages5
Characters14,090
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 13 people and organisations named in the text · linked when the evidence is strong

linked org PYRIDAM FARMA TBK. p.1 ×14
linked org Sinar Mas p.1
linked person dr. WIDJANARKO BROTOSAPUTRO · Commissioner p.1 ×3
linked person YENFRINO GUNADI · Director p.1 ×2
linked person BEDJO STEFANUS · Director p.2 ×2
linked person MAURA LINDA SITANGGANG · Commissioner p.2 ×3
linked person ROBBY YULIANTO · President Commissioner p.2 ×2
linked person ANTES EKO PRASETIO · Director p.5
linked person SINTA LESTARI NINGSIH · Director p.5
possible person CHARLES D. MARPAUNG · Commissioner p.2 ×3
unresolved org Financial Services Authority p.1
unresolved person H. Whereas p.3
unresolved — LEE YAN GWAN · President Director p.5 ×3

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

Rule parser Needs review confidence 0.000 873 ms 12 Sep 2026 22:38

no RUPS minutes content - likely misclassified

↑↓ select ↵ open ⇧↵ see every result